Below is a brief note written by CEO Keith McCullough on why we are removing Exact Sciences (EXAS) from Investing Ideas today:
|
It’s been a great run for us on the long side so I’m going to book the win here and revisit once we get more time and information. On today’s preannounced quarter… overall, we think the higher than expected provider adds and ARPT in Q417 are significant positives and outweigh the sequentially lower tests per provider, but are incrementally cautious on this negative surprise compared to our thesis. |
Since we added Exact Sciences to Investing Ideas in March 2017 shares are up more than 148%.
***Click here to read our analyst's original report.
